Pinned straw:
@Mallers I think it is a demonstration of the market influence of the top Academic Medical Centres. Mayo Clinic is one of the most prestigious.
But it is amazing that a short term trial with no contract values can have such an influence on the share price. This looks to be sentiment on steroids. This announcement of a trial with no contract values has added $900m of shareholder value. Crazy!0
As to $PME, Mayo have full stack Visage for radiology. So, CT:VQ can be integrated into the standard PACS/DICOM integration, as a matter of course, as part of the routine CT workflow.
I don’t think that $4DX CT:VQ is currently/yet available as a Visage Module, but given the ownership stake and distribution agreement this would seem to me to be a natural step in the near term.